Esomeprazole Affects QOL

Published Online: Saturday, October 1, 2005

Gastroesophageal reflux disease (GERD) can significantly impair health-related quality of life (QOL). In their study, F. Pace, MD, and colleagues assessed the effects of esomeprazole (a proton pump inhibitor) therapy on QOL in patients with GERD (n = 6017). Upon enrollment, patients received esomeprazole (40 mg/day) acutely for 4 weeks. If this treatment was successful, they were randomly assigned to 2 maintenance esomeprazole treatment strategies: continuous (20 mg/day) or on demand (for 6 months). QOL was measured at baseline by the generic Short-Form 36 Questionnaire and by a disease-specific instrument, QOL in Reflux and Dyspepsia (QOLRAD).

After the acute treatment phase, all QOLRAD dimensions showed statistically significant (P < .0001) and clinically meaningful improvement. There was a statistically significant but small difference in QOLRAD scores at the end of the maintenance phase in favor of the continuous versus the on-demand regimen. Improved QOL was maintained during the 6-month followup, with patients favoring the continuous- treatment strategy, according to a study in Alimentary Pharmacology & Therapeutics (September 2005).

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues